BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/15/2019 2:56:14 PM | Browse: 860 | Download: 1502
 |
Received |
|
2019-03-22 00:17 |
|
Peer-Review Started |
|
2019-03-22 08:15 |
|
First Decision by Editorial Office Director |
|
2019-05-31 12:12 |
|
Return for Revision |
|
2019-06-03 06:14 |
|
Revised |
|
2019-06-13 17:55 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-06-17 08:41 |
|
Second Decision by Editor-in-Chief |
|
2019-06-18 22:46 |
|
Final Decision by Editorial Office Director |
|
2019-07-27 09:53 |
|
Articles in Press |
|
2019-07-27 09:53 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-08-08 03:09 |
|
Publish the Manuscript Online |
|
2019-08-15 14:56 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role in treatment; from the past to future
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hakan Dogruel and Mustafa Kemal Balci |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hakan Dogruel, MD, Doctor, Doctor, Department of Internal Medicine, Antalya Ataturk State Hospital, Anafartalar street. Number:100, Antalya 07001, Türkiye. dogruelhakan@gmail.com |
| Key Words |
Incretin-based therapy; Incretin mimetics; Glucagon-like peptide-1 receptor agonist; Dipeptidyl peptidase-4 inhibitor; ; |
| Core Tip |
The prevalence of type 2 diabetes and its complications rising dramatically over the last years. It is well known that diabetes and its complications; especially cardiovascular complications lead to increased morbidity and mortality. Treatment options for diabetes have increased as the pathophysiology was understood. We discuss the incretin-based therapy, especially Glucagon-like peptide-1 receptor agonists and the beneficial effects on comorbidities besides glucose lowering effect. |
| Publish Date |
2019-08-15 14:56 |
| Citation |
Dogruel H, Balci MK. Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role in treatment; from the past to future. World J Diabetes 2019; 10(8): 446-453 |
| URL |
https://www.wjgnet.com/1948-9358/full/v10/i8/446.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v10.i8.446 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
